View Post

HHV-6 in Cancer: Does it play a role?

Since its discovery, HHV-6 has been studied in the context of lymphoproliferative disorders and various types of cancer. Several obstacles, particularly the ubiquitous nature of the virus, have made it difficult to determine exactly how HHV-6 might, or might not, be involved in tumor development.

$4 million in prizes for literature reviews that explain Alzheiemer’s

The Oskar Fischer prize is named after a neuropathologist who was the first to describe neuritic plaques in 1907 in Prague. James Truchard, the former CEO and Chairman of National Instruments has donated funds for a prize to scientists who can review the existing medical literature to come up with a theory on what causes Alzheimer’s. Truchard points out that …

Research Priorities

Note: we welcome your input. Please send comments to: Kristin_Loomis@HHV-6Foundation.org PROPOSED NEW PRIORITIES FOR ALZHEIMER’S RESEARCH From the HHV-6A/B & HHV-7 research community This summary was compiled by the HHV-6 Foundation with input from experts on HHV-6A & HHV-7, many of whom serve on our Scientific Advisory Board.  Exploration of HHV-6A and HHV-7 in the development and progression of Alzheimer’s …

View Post

New findings on how HHV-6A/B U94 blocks angiogenesis

The HHV-6 latency gene U94 has been found to block angiogenesis, but the mechanisms behind this phenomenon have been unclear. A team lead by Roberta Rizzo and Elisabetta Caselli in Italy shed light on this process, opening the door to new potential molecular targets to pursue in treating diseases marked by improper vascularization.

View Post

HHV-6A & B dysregulate autophagy differently in HSB-2 cells

A group led by Mara Cirone in Italy found that HHV-6B blocks autophagy in HSB-2 cells. Both HSV-1 and CMV have proteins that block autophagy, and HHV-6B carries genes that are homologues of those encoding for CMV’s anti-autophagy protein. Her next step is to study the impact of both HHV-6A and HHV-6B on autophagy in neuronal cells.

NEJM HIGHLIGHTS A CASE OF HHV-6 REACTIVATION IN DRESS

The NEJM rarely covers HHV-6, but did an excellent case history of this patient with HHV-6 reactivation in conjunction with DRESS. The patient was not treated with an antiviral in spite of a plasma HHV-6 DNA load of 112,836, extensive lymphadenopathy, rash and abnormal liver function tests. What did NEJM get wrong? They stated ciHHV6 could be ruled out because …